These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 4026377)

  • 21. Mast cell density and IL-8 expression in nonlesional and lesional psoriatic skin.
    Jiang WY; Chattedee AD; Raychaudhuri SP; Raychaudhuri SK; Farber EM
    Int J Dermatol; 2001 Nov; 40(11):699-703. PubMed ID: 11737436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective persistence of dermal CD8+ T cells in lesional plaque psoriasis after clobetasol-17 propionate treatment.
    Bovenschen HJ; Vissers WH; Seyger MM; van de Kerkhof PC
    Acta Derm Venereol; 2005; 85(2):113-7. PubMed ID: 15823902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of cellular dermal infiltrates in human cutaneous mastocytosis.
    Mirowski G; Austen KF; Chiang L; Horan RF; Sheffer AL; Weidner N; Murphy GF
    Lab Invest; 1990 Jul; 63(1):52-62. PubMed ID: 2374400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatostatin- and factor XIIIa-immunoreactive cells in psoriasis during clobetasol propionate and calciprotriol treatment.
    Talme T; Schultzberg M; Sundqvist KG; Marcusson JA
    Acta Derm Venereol; 1999 Jan; 79(1):44-8. PubMed ID: 10086858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymphocytes and macrophages of the epidermis and dermis in lesional psoriatic skin, but not epidermal Langerhans cells, are depleted by treatment with cyclosporin A.
    Gupta AK; Baadsgaard O; Ellis CN; Voorhees JJ; Cooper KD
    Arch Dermatol Res; 1989; 281(4):219-26. PubMed ID: 2673064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pruritogenic mediators in psoriasis vulgaris: comparative evaluation of itch-associated cutaneous factors.
    Nakamura M; Toyoda M; Morohashi M
    Br J Dermatol; 2003 Oct; 149(4):718-30. PubMed ID: 14616362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mast cells in acute hepatitis.
    Bardadin KA; Scheuer PJ
    J Pathol; 1986 Aug; 149(4):315-25. PubMed ID: 3761069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cutaneous mast cell depletion results from topical corticosteroid usage.
    Lavker RM; Schechter NM
    J Immunol; 1985 Oct; 135(4):2368-73. PubMed ID: 4031494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis.
    Decroix J; Pres H; Tsankov N; Poncet M; Arsonnaud S
    Cutis; 2004 Sep; 74(3):201-6. PubMed ID: 15499763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mast cell activation and vascular alterations in immediate hypersensitivity-like reactions induced by a T cell-derived antigen-binding factor.
    Kops SK; Van Loveren H; Rosenstein RW; Ptak W; Askenase PW
    Lab Invest; 1984 Apr; 50(4):421-34. PubMed ID: 6608629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mast cell degranulation and elastolysis in the early stage of striae distensae.
    Sheu HM; Yu HS; Chang CH
    J Cutan Pathol; 1991 Dec; 18(6):410-6. PubMed ID: 1774350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis.
    Mashiko S; Bouguermouh S; Rubio M; Baba N; Bissonnette R; Sarfati M
    J Allergy Clin Immunol; 2015 Aug; 136(2):351-9.e1. PubMed ID: 25792465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combining lesional short-contact dithranol therapy of psoriasis with a potent topical corticosteroid.
    Swinkels OQ; Prins M; Kucharekova M; de Boo T; Gerritsen MJ; van der Valk PG; van de Kerkhof PC
    Br J Dermatol; 2002 Apr; 146(4):621-6. PubMed ID: 11966693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and scalp psoriasis.
    Mazzotta A; Esposito M; Carboni I; Schipani C; Chimenti S
    J Dermatolog Treat; 2007; 18(2):84-7. PubMed ID: 17520464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitor of the release of mast cell mediators does not improve the psoriatic plaque.
    van de Kerkhof PC; Goos M; Christophers E; Baudin M; Dupuy P
    Skin Pharmacol; 1995; 8(1-2):25-9. PubMed ID: 7786522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis.
    Jarratt MT; Clark SD; Savin RC; Swinyer LJ; Safley CF; Brodell RT; Yu K
    Cutis; 2006 Nov; 78(5):348-54. PubMed ID: 17186795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ultrastructural changes in human skin mast cells during antigen-induced degranulation in vivo.
    Friedman MM; Kaliner M
    J Allergy Clin Immunol; 1988 Dec; 82(6):998-1005. PubMed ID: 3204257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The skin and the gut in psoriasis: the number of mast cells and CD3+ lymphocytes is increased in non-involved skin and correlated to the number of intraepithelial lymphocytes and mast cells in the duodenum.
    Michaëlsson G; Kraaz W; Hagforsen E; Pihl-Lundin I; Lööf L; Scheynius A
    Acta Derm Venereol; 1997 Sep; 77(5):343-6. PubMed ID: 9298124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Familial urticaria pigmentosa with giant mast cell granules. A clinical, light, and electron microscopic study.
    James MP; Eady RA
    Arch Dermatol; 1981 Nov; 117(11):713-8. PubMed ID: 7316532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T cell-dependent mast cell degranulation and release of serotonin in murine delayed-type hypersensitivity.
    Askenase PW; Bursztajn S; Gershon MD; Gershon RK
    J Exp Med; 1980 Nov; 152(5):1358-74. PubMed ID: 6968811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.